Food Composition Data

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Food composition data PRODUCTION, MANAGEMENT AND USE H. Greenfield and D.A.T. Southgate Second edition Food composition data Food composition data PRODUCTION, MANAGEMENT AND USE by H. Greenfield University of New South Wales, Sydney, Australia and D.A.T. Southgate Formerly of the Agricultural and Food Research Council Institute of Food Research, Norwich, United Kingdom Technical editors: B.A. Burlingame and U.R. Charrondiere Food and Agriculture Organization of the United Nations Rome 2003 Editing, design and production by the FAO Publishing Management Service The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. ISBN 92 5 104949 1 All rights reserved. Reproduction and dissemination of material in this information product for educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Reproduction of material in this information product for resale or other commercial purposes is prohibited without written permission of the copyright holders. Applications for such permission should be addressed to the Chief, Publishing Management Service, Information Division, FAO, Viale delle Terme di Caracalla, 00100 Rome, Italy or by e-mail to [email protected] © FAO 2003 First edition published in 1992 by Elsevier Science Publishers Contents Foreword to the first edition vii Preface to the second edition ix Preface to the first edition xi Acknowledgements xii Introduction 1 Chapter 1 Food composition data and food composition databases 5 Chapter 2 Initiation and organization of a food composition programme 21 Chapter 3 Selection of foods 33 Chapter 4 Selection of nutrients and other components 47 Chapter 5 Sampling 63 Chapter 6 Choice of analytical methods and their evaluation 83 Chapter 7 Review of methods of analysis 97 Chapter 8 Assuring the quality of analytical data 149 Chapter 9 Conventions and modes of expression of food composition data 163 Chapter 10 Guidelines for the use of food composition data 171 Chapter 11 Quality considerations in the compilation of a food composition data base 187 Chapter 12 Current needs and future directions 199 Appendixes Appendix 1 INFOODS regional data centres 209 Appendix 2 Calculation of sample numbers 214 Appendix 3 Methods of preparation of foods for analysis 216 Appendix 4 Examples of procedures for the preparation of analytical samples 221 Appendix 5 Calculations of fatty acids in 100 g food and 100 g total fatty acids 223 Appendix 6 Calculation of the composition of dishes prepared from recipes 225 Appendix 7 Essential book list for food composition databases 226 Bibliography 229 Subject index 281 vii Foreword to the first edition About 20 years ago, there was a recognition in Europe that real benefits would flow from coordinating the manner in which food composition tables were produced in the various countries of Europe. Subsequent development of computerized nutritional databases has further highlighted the potential advantages of working together. Such cooperation could lead to improved quality and compatibility of the various European nutrient databases and the values within them. This realization was one of the driving forces behind the development of the EUROFOODS initiative in the 1980s when those people in Europe interested in data on food composition began working together. This initiative received further impetus with the establishment of the EUROFOODS-Enfant Concerted Action Project within the framework of the FLAIR (Food-Linked Agro-Industrial Research) Programme of the Commission of the European Communities. It was quickly recognized that the draft guidelines for the production, management and use of food composition data, which had been prepared under the aegis of INFOODS (International Network of Food Data Systems, a project of the United Nations University), would be especially applicable to the objectives of the Concerted Action. The guidelines have been written by two recognized experts. Many people associated with FLAIR EUROFOODS- Enfant have added constructive criticism and advice to that offered previously by those associated with INFOODS. Thus the guidelines are backed by a consensus in the community of those responsible for the production and use of food composition tables and nutrient databases. I am sure that the book will be regarded by those concerned with the production and use of nutritional compositional data as a lighthouse on an ocean with poor visibility, many hazards and shipwrecks. It will provide invaluable light not only for people in Europe but also for those on other continents across the oceans. Clive E. West Project Manager FLAIR EUROFOODS-Enfant Project Wageningen, February 1992 ix Preface to the second edition The first edition of this book was used extensively in training food composition analysts and compilers around the world, commencing with the first Food Composition training course held in Wageningen, the Netherlands, in October 1992. Five courses have been held subsequently in Wageningen and the course has also been transferred to developing regions including one each in Chile for LATINFOODS countries, Jamaica for CARICOMFOODS countries, Thailand for ASEANFOODS and SAARCFOODS countries, and three in South Africa for the countries of ECSAFOODS. The use of the book in the United Nations University/INFOODS training courses revealed that changes were required to update the text and figures, in particular to make the book more user-friendly on an international basis. Increasingly, as time went by, the huge explosion in methods of analysis meant that the book was becoming rapidly out-of-date. Further, the establishment of food composition programmes around the world increased the pool of experience available. However, revision was not feasible as a commercial project. Although some tertiary courses, largely in the industrialized countries, were able to draw on the book in teaching, the prohibitive cost of the first edition meant that purchases of the book were mainly for libraries rather than by individuals or for local food composition programmes. When the first edition became out of print, the copyright reverted to the original authors. In 2001, Dr Barbara Burlingame, the Director of INFOODS (Food and Agriculture Organization of the United Nations [FAO]), proposed a rescue package – which was taken up eagerly by the authors. The proposal was for the authors to revise and update the first edition in the light of the comments of trainees in the course over the previous decade, and to incorporate improved methods of analysis (while not excluding those older methods, which were still being used satisfactorily in those parts of the world where access to sophisticated and costly instrumentation was limited). It was also proposed that FAO make the print edition of the book available at an affordable price, oversee its translation into the main languages of the United Nations Organizations and, further, place the book on the FAO Web site for worldwide access. The authors were pleased to accept this proposal since the original concept of the book had always been wide availability at a price that placed it within the reach of students and workers, particularly those in developing countries. The second edition was largely prepared by means of electronic communication inter- spersed with occasional face-to-face meetings to establish the roles of the authors and FAO and identify the new or revised material to include. David Southgate worked from a very large literature database compiled by Heather Greenfield for the period 1990 to the present, together with his unparalleled experience in the compilation of the United Kingdom tables x Food composition data and discussions with trainees in courses held in the Netherlands and other parts of the world, to collate the first comprehensive draft of the revised edition, which included particular sections drafted by Heather Greenfield and inputs from members of the INFOODS mailing list. A meeting of the authors with Barbara Burlingame in Norwich, United Kingdom, made possible an extensive review of the text, particularly to incorporate elements required by FAO. The draft chapters were reviewed by experts and the final version for publication was prepared through a long process of careful checking and revision conducted by Heather Greenfield, Barbara Burlingame and Ruth Charrondiere (FAO), working in collaboration by e-mail correspondence and, where possible, consultation with all the original sources of information. Barbara Burlingame oversaw the preparation of the final text for publication in various formats at FAO. As in the first edition, the personal perspectives and prejudices of the authors doubtless show through. We believe that there is no a priori method of obtaining compositional data without analysis. The book recognizes that analytical facilities and resources are limited in virtually all countries and that, at the same time, there is a large amount of compositional data in the literature, in both published and unpublished sources and in other databases. It is essential to make proper use of this material. The book therefore devotes a considerable amount of attention to
Recommended publications
  • Ruthenium-Catalyzed CH Functionalization Of(Hetero)

    Ruthenium-Catalyzed CH Functionalization Of(Hetero)

    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1465 Ruthenium-catalyzed C-H Functionalization of (Hetero)arenes KARTHIK DEVARAJ ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6214 ISBN 978-91-554-9783-5 UPPSALA urn:nbn:se:uu:diva-310998 2017 Dissertation presented at Uppsala University to be publicly examined in B22, BMC, Husargatan 3, Uppsala, Uppsala, Friday, 24 February 2017 at 09:30 for the degree of Doctor of Philosophy. The examination will be conducted in English. Faculty examiner: Professor Victor A. Snieckus (Department of Chemistry, Queen's University, Canada). Abstract Devaraj, K. 2017. Ruthenium-catalyzed C-H Functionalization of (Hetero)arenes. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1465. 59 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9783-5. This thesis concerned about the Ru-catalyzed C-H functionalizations on the synthesis of 2- arylindole unit, silylation of heteroarenes and preparation of aryne precursor. In the first project, we developed the Ru-catalyzed C2-H arylation of N-(2-pyrimidyl) indoles and pyrroles with nucleophilic arylboronic acids under oxidative conditions. Wide variety of arylboronic acids afforded the desired product in excellent yield regardless of the substituents or functional group electronic nature. Electron-rich heteroarenes are well suited for this method than electron-poor heteroarenes. Halides such as bromide and iodide also survived, further derivatisation of the halide is shown by Heck alkenylation. In order to find catalytic on-cycle intermediate extensive mechanistic experiments have been carried out by preparing presumed ruthenacyclic complexes and C-H/D exchange reactions.
  • Article Download

    Article Download

    wjpls, 2020, Vol. 6, Issue 8, 61-75 Review Article ISSN 2454-2229 Mitali et al. World Journal of Pharmaceutical and Life Science World Journal of Pharmaceutical and Life Sciences WJPLS www.wjpls.org SJIF Impact Factor: 6.129 INSULIN THERAPY AND IT’S NEW APPROACHES Tejaswini S. Kawanpure and Dr. Mitali M. Bodhankar* Gurunanak College of Pharmacy, Near Dixit Nagar, Nari Road, Nagpur- 440026. Corresponding Author: Dr. Mitali M. Bodhankar Gurunanak College of Pharmacy, Near Dixit Nagar, Nari Road, Nagpur- 440026. Article Received on 01/06/2020 Article Revised on 22/06/2020 Article Accepted on 12/07/2020 ABSTRACT Diabetes mellitus is a serious pathologic condition which is responsible for major healthcare problems worldwide Insulin replacement therapy has been used in the clinical Management of diabetes mellitus for more than 84 years. Insulin has remained indispensable in dispensable in management of diabetes mellitus since its discovery in 1921. Comparatively, a large percentage of world population is affected by diabetes mellitus, out of which approximately 5-10% with type 1 diabetes while the remaining 90% with type 2. The present mode of insulin administration is by the subcutaneous route through which insulin introduced into the body in a non-physiological manner having many challenges. Hence novel approaches for insulin delivery are being explored. Challenges that have adverse effect on oral route of insulin administration mainly includes rapid enzymatic degradation in the stomach, inactivation and digestion by proteolytic enzymes in the intestinal lumen and poor permeability across intestinal epithelium because of its high molecular weight and its lipophilicity. Approaches such as liposomes, micro emulsions, nano cubicle, insulin chewing gum and so forth have been prepared to ensure the oral delivery of insulin.
  • FOODINTEGRITY Ensuring the Integrity of the European Food Chain

    FOODINTEGRITY Ensuring the Integrity of the European Food Chain

    FOODINTEGRITY Ensuring the Integrity of the European food chain 613688: Collaborative Project Seventh Framework Programme KBBE.2013.2.4-01: Assuring quality and authenticity in the food chain Deliverable: 14.1 Title: Report on development of chemical and metabolomic markers of product integrity and stability along processing. Author(s): Baroni, María Verónica; Erban, Alexander; Kopka, Joachim; Wunderlin, Daniel Beneficiary(s): Food Integrity Consortia Date of preparation: September 21th 2017. Period covered: November-2016; August-2017 Status: version 1 Dissemination level PU Public X PP Restricted to other participants RE Restricted to a group specified by the consortium CO Confidential, only members of the consortium The project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No. 613688. Deliverable 14.1, version 1, 21‐09‐2017 Deliverable 14.1 Report on development of chemical and metabolomic markers of product integrity and stability along processing. TABLE OF CONTENTS Page Nr. 1 Description of Deliverable 3 2 Achievement of the Deliverable 3 2.1 Chemical fractionation and profiling of seeds for the discovery of potential chemical markers by GC-MS (MPIMP). 3 2.1.1 Seed selection (EU market). 3 2.1.2 Fractionation scheme to evaluate chemical markers in seeds 4 2.1.3 Evaluation of chemical markers in seeds by GC-MS and chemometrics 5 2.2 Chemical fractionation and profiling of seeds, and bakery products containing seeds, for the discovery of potential chemical markers by LC-MS (CONICET-ICYTAC). 10 2.2.1 Seed sampling, extraction and analytical procedures (AR mark et).
  • Supplementary Information

    Supplementary Information

    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
  • Issues in Environmental Science and Technology

    Issues in Environmental Science and Technology

    ISSUES IN ENVIRONMENTAL SCIENCE AND TECHNOLOGY EDITORS: R. E. HESTER AND R. M. HARRISON 12 ROYAL SOCIETY OF CHEMISTRY ISBN 0-85404-255-5 ISSN 1350-7583 A catalogue record for this book is available from the British Library @ The Royal Society of Chemistry 1999 All rights reserved Apart from any lair dealing for the purposes of research or private study, or criticism or review as permitted under the terms of the UK Copyright, Designs and Patents Act, 1988, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Societ}' of Chemistry, or in the case ofreprographic reproduction only in accordance with the terms of the licence.~ issued b}' the Cop}Tight Licensing Agenc}' in the UK, or in accordance Ilith the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the addre.~.~ printed on this page. Published by The Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge CB4 OWF, UK For further information see our web site,at www.rsc.org Typeset in Great Britain by Vision Typesetting, Manchester Printed and bound by Redwood Books Ltd., Trowbridge, Wiltshire Editors Ronald E. Hester, BSc, DSc(London), PhD(Cornell), FRSC, CChem Ronald E. Rester is Professor of Chemistry in the University of York. He was for short periods a research fellow in Cam bridge and an assistant professor at Cornell before being appointed to a lectureship in chemistry in Y orkin 1965.
  • Natural Products As Alternative Choices for P-Glycoprotein (P-Gp) Inhibition

    Natural Products As Alternative Choices for P-Glycoprotein (P-Gp) Inhibition

    Review Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition Saikat Dewanjee 1,*, Tarun K. Dua 1, Niloy Bhattacharjee 1, Anup Das 2, Moumita Gangopadhyay 3, Ritu Khanra 1, Swarnalata Joardar 1, Muhammad Riaz 4, Vincenzo De Feo 5,* and Muhammad Zia-Ul-Haq 6,* 1 Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India; [email protected] (T.K.D.); [email protected] (N.B.); [email protected] (R.K.); [email protected] (S.J.) 2 Department of Pharmaceutical Technology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 3 Department of Bioechnology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 4 Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal 18050, Pakistan; [email protected] 5 Department of Pharmacy, Salerno University, Fisciano 84084, Salerno, Italy 6 Environment Science Department, Lahore College for Women University, Jail Road, Lahore 54600, Pakistan * Correspondence: [email protected] (S.D.); [email protected] (V.D.F.); [email protected] (M.Z.-U.-H.) Academic Editor: Maria Emília de Sousa Received: 11 April 2017; Accepted: 15 May 2017; Published: 25 May 2017 Abstract: Multidrug resistance (MDR) is regarded as one of the bottlenecks of successful clinical treatment for numerous chemotherapeutic agents. Multiple key regulators are alleged to be responsible for MDR and making the treatment regimens ineffective. In this review, we discuss MDR in relation to P-glycoprotein (P-gp) and its down-regulation by natural bioactive molecules. P-gp, a unique ATP-dependent membrane transport protein, is one of those key regulators which are present in the lining of the colon, endothelial cells of the blood brain barrier (BBB), bile duct, adrenal gland, kidney tubules, small intestine, pancreatic ducts and in many other tissues like heart, lungs, spleen, skeletal muscles, etc.
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0220631 A1 Mezey Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2016/0220631 A1 Mezey Et Al

    US 2016O220631A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0220631 A1 Mezey et al. (43) Pub. Date: Aug. 4, 2016 (54) METHODS OF MODULATING Publication Classification ERYTHROPOESS WITH ARGINNE VASOPRESSIN RECEPTOR 1B MOLECULES (51) Int. Cl. A638/II (2006.01) (71) Applicant: THE USA, AS REPRESENTED BY A613 L/404 (2006.01) THE SECRETARY DEPARTMENT A613 L/46.5 (2006.01) OF HEALTH AND HUMAN A638/8 (2006.01) SERVICES, Bethesda, MD (US) A6II 45/06 (2006.01) (52) U.S. Cl. (72) Inventors: Eva M. Mezey, Rockville, MD (US); CPC ............. A61K 38/11 (2013.01); A61 K38/1816 Balazs Mayer, Budakeszi (HU); (2013.01); A61K 45/06 (2013.01); A61 K Krisztian Nemeth, Budapest (HU); 3 1/465 (2013.01); A61 K31/404 (2013.01) Miklos Krepuska, Rockville, MD (US) (73) Assignee: The USA, as represented by the (57) ABSTRACT Secretary, Departm-ent of Health and Disclosed are methods of modulating erythropoiesis with Human Service, Bethesda, MD (US) arginine vasopressin receptor 1B (AVPR1B) molecules, such Appl. No.: as AVPR1B agonists or antagonists. In one example, a (21) 15/022,531 method of stimulating erythropoiesis is disclosed including (22) PCT Fled: Oct. 1, 2014 administering an effective amount of an AVPR1B stimulatory molecule to a subject in need thereof, thereby stimulating (86) PCT NO.: PCT/US2O14/058613 erythropoiesis. Also disclosed is a method of stimulating hematopoetic stem cell (HSC) proliferation which includes S371 (c)(1), administering an effective amount of an AVPR1B stimulatory (2) Date: Mar. 16, 2016 molecule to a subject in need thereof, thereby stimulating HSC proliferation.
  • Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor. Christophe Leterrier, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei

    Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor. Christophe Leterrier, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei

    Constitutive endocytic cycle of the CB1 cannabinoid receptor. Christophe Leterrier, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei To cite this version: Christophe Leterrier, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei. Constitutive endocytic cycle of the CB1 cannabinoid receptor.. Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2004, 279 (34), pp.36013-36021. 10.1074/jbc.M403990200. hal-00250336 HAL Id: hal-00250336 https://hal.archives-ouvertes.fr/hal-00250336 Submitted on 6 Feb 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Supplemental Material can be found at: http://www.jbc.org/cgi/content/full/M403990200/DC1 THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 34, Issue of August 20, pp. 36013–36021, 2004 © 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A. Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor*□S Received for publication, April 9, 2004, and in revised form, June 9, 2004 Published, JBC Papers in Press, June
  • Enterolactone Induces Apoptosis in Human Prostate Carcinoma Lncap Cells Via a Mitochondrial-Mediated, Caspase-Dependent Pathway

    Enterolactone Induces Apoptosis in Human Prostate Carcinoma Lncap Cells Via a Mitochondrial-Mediated, Caspase-Dependent Pathway

    2581 Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway Li-Hua Chen,1 Jing Fang,1 Huaixing Li,1 United States and China (1, 2). Diet is considered a primary Wendy Demark-Wahnefried,2 and Xu Lin1 factor contributing to the huge differential in the preva- lence of prostatic carcinoma (3). Although there are several 1 Institute for Nutritional Sciences, Shanghai Institutes for dietary factors that may be important for this disease, we Biological Sciences, Chinese Academy of Sciences, and Graduate School of the Chinese Academy of Sciences, Shanghai, China; propose a study that specifically focuses on dietary lignans and 2School of Nursing and Department of Surgery, Duke because the traditional plant-based diet in Asia is rich University Medical Center, Durham, North Carolina in lignans as compared with the omnivorous diet of the United States and Northern Europe (4). Moreover, our previous studies suggest an inhibitory effect of this Abstract phytochemical on prostate cancer growth (5). The mammalian lignan enterolactone is a major metabolite Dietary lignans have phytoestrogenic properties (6) and of plant-based lignans that has been shown to inhibit the are broadly available in cereals, legumes, fruits, vegetables, growth and development of prostate cancer. However, and grains, with the highest concentration in flaxseed and little is known about the mechanistic basis for its anti- sesame seeds (7, 8). Plant-based lignans, secoisolariciresinol cancer activity. In this study, we report that enterolactone and matairesinol, are converted by the intestinal microflora selectively suppresses the growth of LNCaP prostate to mammalian lignans of enterodiol and enterolactone, the cancer cells by triggering apoptosis.
  • Phenolic Compounds in Cereal Grains and Their Health Benefits

    Phenolic Compounds in Cereal Grains and Their Health Benefits

    and antioxidant activity are reported in the Phenolic Compounds in Cereal literature. Unfortunately, it is difficult to make comparisons of phenol and anti- Grains and Their Health Benefits oxidant activity levels in cereals since different methods have been used. The ➤ Whole grain cereals are a good source of phenolics. purpose of this article is to give an overview ➤ Black sorghums contain high levels of the unique 3-deoxyanthocyanidins. of phenolic compounds reported in whole ➤ Oats are the only source of avenanthramides. grain cereals and to compare their phenol and antioxidant activity levels. ➤ Among cereal grains, tannin sorghum and black rice contain the highest antioxidant activity in vitro. Phenolic Acids Phenolic acids are derivatives of benzoic and cinnamic acids (Fig. 1) and are present in all cereals (Table I). There are two Most of the literature on plant phenolics classes of phenolic acids: hydroxybenzoic L. DYKES AND L. W. ROONEY focuses mainly on those in fruits, acids and hydroxycinnamic acids. Hy- TEXAS A&M UNIVERSITY vegetables, wines, and teas (33,50,53,58, droxybenzoic acids include gallic, p- College Station, TX 74). However, many phenolic compounds hydroxybenzoic, vanillic, syringic, and in fruits and vegetables (i.e., phenolic acids protocatechuic acids. The hydroxycinna- esearch has shown that whole grain and flavonoids) are also reported in cereals. mic acids have a C6-C3 structure and Rconsumption helps lower the risk of The different species of grains have a great include coumaric, caffeic, ferulic, and cardiovascular disease, ischemic stroke, deal of diversity in their germplasm sinapic acids. The phenolic acids reported type II diabetes, metabolic syndrome, and resources, which can be exploited.
  • Engagement of Β-Arrestin by Transactivated Insulin-Like Growth Factor Receptor Is Needed for V2 Vasopressin Receptor-Stimulated ERK1/2 Activation

    Engagement of Β-Arrestin by Transactivated Insulin-Like Growth Factor Receptor Is Needed for V2 Vasopressin Receptor-Stimulated ERK1/2 Activation

    Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation Geneviève Oligny-Longpréa, Maithé Corbanib, Joris Zhoua, Mireille Hoguea, Gilles Guillonb, and Michel Bouviera,1 aInstitut de Recherche en Immunologie et Cancérologie, Département de Biochimie and Groupe de Recherche Universitaire sur le Médicament, Universitéde Montréal, Montréal, QC, Canada H3C 3J7; and bInstitut de Génomique Fonctionnelle, Département d’Endocrinologie, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5203, Institut National de la Santé et de la Recherche Médicale Unité 661, Universités Montpellier I et II, 34094 Montpellier Cedex 05, France Edited* by Jean-Pierre Changeux, Institut Pasteur, Paris, France, and approved March 9, 2012 (received for review August 12, 2011) G protein-coupled receptors (GPCRs) have been shown to activate ceptor (EGFR) and has only been described for EGFR ligands the mitogen-activated protein kinases, ERK1/2, through both G thus far (5, 6). Although GPCR-mediated transactivation of protein-dependent and -independent mechanisms. Here, we de- several other RTKs [including the PDGF (7), FGF (8), VEGF scribe a G protein-independent mechanism that unravels an un- (9), and tropomyosin-receptor kinase A (TrkA) (10) receptors] anticipated role for β-arrestins. Stimulation of the V2 vasopressin leading to MAPK activation has been documented, the specific receptor (V2R) in cultured cells or in vivo in rat kidney medullar mechanism responsible for the RTK engagement remains poorly collecting ducts led to the activation of ERK1/2 through the metal- characterized. Intracellular scaffolding that promotes the forma- loproteinase-mediated shedding of a factor activating the insulin- tion of protein complexes with nonreceptor tyrosine kinases, such – like growth factor receptor (IGFR).
  • Overview of the Anti-Inflammatory Effects, Pharmacokinetic Properties

    Overview of the Anti-Inflammatory Effects, Pharmacokinetic Properties

    Acta Pharmacologica Sinica (2018) 39: 787–801 © 2018 CPS and SIMM All rights reserved 1671-4083/18 www.nature.com/aps Review Article Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L Qiong GAO, Mengbi YANG, Zhong ZUO* School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China Abstract Arctigenin (AR) and its glycoside, arctiin, are two major active ingredients of Arctium lappa L (A lappa), a popular medicinal herb and health supplement frequently used in Asia. In the past several decades, bioactive components from A lappa have attracted the attention of researchers due to their promising therapeutic effects. In the current article, we aimed to provide an overview of the pharmacology of AR and arctiin, focusing on their anti-inflammatory effects, pharmacokinetics properties and clinical efficacies. Compared to acrtiin, AR was reported as the most potent bioactive component of A lappa in the majority of studies. AR exhibits potent anti-inflammatory activities by inhibiting inducible nitric oxide synthase (iNOS) via modulation of several cytokines. Due to its potent anti-inflammatory effects, AR may serve as a potential therapeutic compound against both acute inflammation and various chronic diseases. However, pharmacokinetic studies demonstrated the extensive glucuronidation and hydrolysis of AR in liver, intestine and plasma, which might hinder its in vivo and clinical efficacy after oral administration. Based on the reviewed pharmacological and pharmacokinetic characteristics of AR, further pharmacokinetic and pharmacodynamic studies of AR via alternative administration routes are suggested to promote its ability to serve as a therapeutic agent as well as an ideal bioactive marker for A lappa.